Jun 12 |
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
|
May 16 |
bioAffinity Technologies GAAP EPS of -$0.21, revenue of $2.4M
|
May 15 |
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
|
Apr 24 |
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
|
Apr 9 |
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
|
Apr 4 |
bioAffinity Technologies files to sell 1.63M shares for holders
|
Apr 1 |
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 8 |
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
|
Mar 8 |
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
|
Mar 6 |
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
|